Sunday 22 December 2024

The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's

Biotechnology
Simon Wentworth
17 July 2023
pharma_letter_podcast_24

More on this story...

Biotechnology
New Alzheimer's therapies ready for battle at AAIC 2023
12 July 2023
Biotechnology
BRIEF—AAIC 2023: Prothena offers data on BMS-partnered antibody
12 July 2023
Pharmaceutical
Lilly tops pharma in market cap after 36% growth
21 August 2023
Biotechnology
Coya Therapeutics expands COYA 302 into Alzheimer’s disease
21 February 2024


Companies featured in this story

More ones to watch >


Today's issue

The week in pharma: action, reaction and insight – week to December 20
Pharmaceutical
The week in pharma: action, reaction and insight – week to December 20
22 December 2024
Biotechnology
FDA approves Novo Nordisk’s Alhemo
22 December 2024
Pharmaceutical
Italfarmaco’s Duvyzat backed by MHRA
22 December 2024
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

FDA approves Novo Nordisk’s Alhemo
22 December 2024
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze